Placenta AccretaACCSSNCT05070689
Placenta Accreta Spectrum Disorders: A. Chohan Continuous Squeezing Suture (ACCSS)
A study testing ACCSS in people with Placenta Accreta, run by Sharif Medical Research Center at 1 site in Pakistan.
Trial summary
Placenta Accreta Spectrum (PAS) disorders are rising in incidence due to increased rate of repeat caesarean sections. Peripartum hysterectomy remains the only definitive treatment of massive postpartum haemorrhage related to this condition. Read more about this study
- Who is it for?
- Ages 18 to 35 years, women only
- Conditions the study is for
- Placenta Accreta
- What is being tested?
- ACCSS
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 sitePakistan
- Study dates
- 15 Nov 2021to 31 May 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- The women at 32 weeks' gestation with central (anterior dominant, posterior) placenta praevia.
- The women with Placenta Accreta Spectrum disorders having myometrial invasion limited to the uterine serosa (Grade 1, 2, and 3a) without involvement of urinary bladder and other pelvic organs.
- The women wishing to conserve the uterus at the time of caesarean section.
Who cannot join
- The patients with placenta accreta spectrum disorder with bladder and other organs involvement (Grade 3b, 3c) diagnosed prenatally and during caesarean section.
- The patients with laterally situated right and left placentae.
- The recruited patients who required emergency caesarean section.
Trial locations and contacts
1 site in 1 country.
Pakistan1 site, 1 recruiting
- Recruiting
Sharif Medical and Dental college
Lahore, Pakistan/Punjab, 54000
Muhammad Arshad Chohan, FCPS, FRCOG, +923004027250, marshadchohan@hotmail.com
Fauzia Butt, FCPS, +923009427094, drfauziabutt@hotmail.com
About this study
Official title: Placenta Accreta Spectrum Disorders: A. Chohan Continuous Squeezing Suture (ACCSS) for Controlling Haemorrahge From Lower Uterine Segment at Caesarean Section
Placenta Accreta Spectrum (PAS) disorders are rising in incidence due to increased rate of repeat caesarean sections. Peripartum hysterectomy remains the only definitive treatment of massive postpartum haemorrhage related to this condition. Researchers have described conservative treatments in the form of pelvic devascularization under radiological control, myometrial resection with placenta in situ, and various suturing techniques some involving inversion of cervix. Variable success rates are described, but search continues for a simple, safe and effective treatment. The objective of this study is to assess the simplicity, safety and efficacy of A. Chohan Continuous Squeezing Suture (ACCSS) in the management of PAS.
Read the detailed description
Placenta accreta spectrum has opened up a new era in the history of PPH, as forcible separation of adherent placenta leads to massive bleeding from placental bed . Peripartum hysterectomy has emerged as gold standard treatment for this variety of PPH (3 folds rise over uterine atony) with its overall morbidity of 40-50%, and mortality of 7-10% in case of placenta percreta . The fear of placental bed bleeding has led to the development of conservative management like "leaving the placenta in situ approach" with its wide range of mild to severe, and serious morbidities . The conservative surgical techniques (The triple P procedure, one step conservative surgery approach) have also used the concept of non-separation of placenta and have instead adopted resection of myometrium with placenta in situ . These surgeries involve devascularisation of deep pelvic / major abdominal vessels and ligation of complex arterial anastomosis making the procedure technically difficult. Moreover, the devascularisation is done under extensive and expensive interventional radiological equipment which places the procedures out of reach for the routine setups particularly in the under developed countries. Another conservative surgical technique (stepwise surgical approach) , which described separation of placenta also mainly relied upon devascularisation of pelvic organs by bilateral ligation of anterior branch of internal iliac artery rather than elaborating the details of technique of controlling haemorrhage at the actual bleeding site.
Rationale of ACCSS ACCSS is a novel suturing technique addresses the management of placenta praevia and PAS following the orthodox approach of separation of placenta, taking the challenge of controlling massive haemorrhage. The rational of ACCSS is; i. Placental bed is the ultimate area of concern in women with placenta praevia and PAS, and it generally spreads over the whole inner surface of lower uterine segment, but the placental attachment and bleeding area upon its separation does not extend onto the internal os and into the vagina.
ii. Lower uterine segment is thin, flexible, squeezable and holds the suture well.
iii. Internal cervical os is a fixed structure, and has a ring with sufficient strength to function as anchor to the suture.
iv. Taking half thickness of internal cervical os into suture does not alter the anatomy and uterine drainage remains unaffected.
- Deep pelvic devascularization by ligation or balloon tamponade occlusion (under radiological control) of deep pelvic vessels was not the part of ACCSS procedure. Bilateral uterine artery ligation was added to it because occlusion of the uterine artery or its branches is useful procedure to stop upper uterine bleeding , it does not appear to affect fertility or obstetric outcome and vascular occlusion is only temporary, as recanalization soon ensures normal uterine circulation . The haemostatic effect of ACCSS is therefore independent and does not rely upon supportive measures.
SURGICAL PROCEDURE The caesarean sections in this study will be performed between 37 and 38 weeks of gestation on all patients. Haematology department will be placed on alert with availability of 4 units of cross matched fresh blood and fresh frozen plasma. All surgeries will be performed by principal investigators (Prof Dr. Arshad Chohan \& Prof. Dr. Fauzia). A multidisciplinary team comprising of experienced obstetricians, anaesthetist, and paediatrician will be involved during the procedure. Prophylactic antibiotic (ceftriaxone 1gm intravenously) will be administered to all patients before surgery.
At caesarean section Pfannenstiel incision will be used for all patients. After opening the abdomen, a clinical assessment about the depth of invasion of the placenta will be made to exclude the involvement of bladder and other pelvic organs. The features noted at this assessment will be abnormal placental bulge and hypervascularity on uterine serosal surface, and placental invasion into the urinary bladder and/or other pelvic organs. Prior to uterine incision placental site will be gently reconfirmed with the examining hand to ascertain an easy fetal access and to avoid cutting of placenta particularly in case of anterior dominant placenta. A transverse incision will be given in the lower uterine segment (LUS) above the insertion of placenta and the baby will be delivered. At delivery of baby10 iu of oxytocin will be given intravenously, followed by 40 iu in 500 ml of normal saline at the rate of 125ml/hour for first 24 hours as per hospital policy for caesarean section for PAS. The uterus will be exteriorized without making any efforts to remove the placenta. The bleeding edges of the uterine incision will be held with Green-Armitage forceps to minimize bleeding. The visceral peritoneum will be displaced downwards with sharp and blunt dissection to allow suturing on the inner side of the LUS. Bladder will be dissected away only if found adherent with the lower uterine segment from previous caesarean sections. Uterine arteries will be ligated on both sides and any blood vessels on the way will be secured. The placenta will then be removed to as close to complete as possible. The lower uterine segment will be packed with sponge to arrest haemorrhage temporarily while preparing for the suture.
ACCSS Application The packing will be removed and the ring of internal os will be identified with the index and middle finger of one hand and held with Babcock forceps with the other hand. On the exposed inner surface of the LUS, suturing will be started from the left corner of uterine incision, using half circle 40mm round body polyglactin 910 suture # 1 (vicryl plus by Ethicon ®) taking multiple half cm bites through half-thickness of the tissue at half cm intervals to reach the outer half of ring of internal os. The suture will then tied and first knot secured causing squeezing of uterine tissue. From here onwards similar sutures will be placed continuously at 1 cm distance till the right corner will be reached, where the second knot will be secured. During suturing the patency of the internal os will be ensured. The continued pull on the suture is expected to cause squeezing of the LUS and arrest bleeding from all sinuses present at the placental site . A similar suture will be applied on the posterior uterine wall in case of bleeding from posterior uterine wall. The suture will be started from the outer half of the posterior lip of the ring of the internal os and going up to the highest bleeding point on the posterior wall of the uterus, continuing from the left to right end of the uterine incision . Any leftover bleeding points will be secured with separate sutures to ensure complete haemostasis. The uterine incision will be closed in two layers as done in a routine lower segment caesarean section. Any additional medical or surgical therapy instituted will be recorded.
- Conditions
- Placenta Accreta
- Being tested
- ACCSS
- Keywords
- Peripartum Hystrectomy, Postpartum Haemorrhage
- Medical subject headings
- Placenta Accreta, Postpartum Hemorrhage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ACCSSProcedure or surgery
- Chohan Continuous Squeezing Suture (ACCSS)
| Study group | Role | What they receive |
|---|---|---|
| Single Group | Experimental | A. Chohan Continuous squeezing Suture (ACCSS): An obstetrical procedure using half circle 40mm round body polyglactin 910 suture # 1 (Vicryl plus by Ethicon ®) for control of haemorrhage from the lower segment, in patients with Placenta Accreta for the prevention of hysterectomy at caesarean section Receives: Procedure: ACCSS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Peripartum Hysterectomy
Absolute number of peripartum hysterectomies within the study group
Measured: 24 hours
Secondary outcomes (9)
Application time of suture in minutes
Application time of suture plus time to complete haemostasis in minutes
Measured: within 20 minutes
Estimated blood loss
Estimate of blood loss in milliliters (ml) intraoperatively and within first 24 hours
Measured: First 24 hours
Number of units of blood transfusions
Number of blood transfusions intraoperatively and within first 24 hours
Measured: First 24 hours
Intensive care unit admissions
Number of days of admission in Intensive care unit
Measured: 7 days
Duration of stay in hospital
Duration of stay in hospital in days
Measured: 7 days
Urinary tract trauma and its complication
Bladder trauma/ vesicovaginal fistula
Measured: 6 weeks
Uterine complications
Uterine necrosis/abscess formation
Measured: 6 weeks
Secondary postpartum hemorrhage
Abnormal uterine bleeding within 6 weeks
Measured: 6 weeks
Maternal mortality
Number of mothers dying in relation to cesarean section within 6 completed weeks
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Oct 2021
- Study start15 Nov 2021
- Primary completion14 Apr 2022 (estimated)
- Study completion31 May 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Placenta AccretaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sharif Medical Research Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Muhammad Arshad Chohan, FRCOG, Principal investigator, Sharif Medical And Dental College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05070689
- Sponsor's protocol ID
- SMDC/SMRC/209-21
- Acronym
- ACCSS
- Status last verified
- Aug 2021
- First submitted
- 27 Sep 2021
- Last updated
- 19 Jan 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Ngwenya S. Postpartum hemorrhage: incidence, risk factors, and outcomes in a low-resource setting. Int J Womens Health. 2016 Nov 2;8:647-650. doi: 10.2147/IJWH.S119232. eCollection 2016.
PubMed 27843354Jauniaux E, Gronbeck L, Bunce C, Langhoff-Roos J, Collins SL. Epidemiology of placenta previa accreta: a systematic review and meta-analysis. BMJ Open. 2019 Nov 12;9(11):e031193. doi: 10.1136/bmjopen-2019-031193.
PubMed 31722942Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, Fox KA, Collins S; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2019 Jul;146(1):20-24. doi: 10.1002/ijgo.12761.
PubMed 31173360Huque S, Roberts I, Fawole B, Chaudhri R, Arulkumaran S, Shakur-Still H. Risk factors for peripartum hysterectomy among women with postpartum haemorrhage: analysis of data from the WOMAN trial. BMC Pregnancy Childbirth. 2018 May 29;18(1):186. doi: 10.1186/s12884-018-1829-7.
PubMed 29843627Palacios-Jaraquemada JM, Fiorillo A, Hamer J, Martinez M, Bruno C. Placenta accreta spectrum: a hysterectomy can be prevented in almost 80% of cases using a resective-reconstructive technique. J Matern Fetal Neonatal Med. 2022 Jan;35(2):275-282. doi: 10.1080/14767058.2020.1716715. Epub 2020 Jan 26.
PubMed 31984808
Study at a glance
From the registry record, last updated by the sponsor on 19 Jan 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Placenta Accreta Spectrum Disorders: A. Chohan Continuous Squeezing Suture (ACCSS) for Controlling Haemorrahge From Lower Uterine Segment at Caesarean Section
- ClinicalTrials.gov ID
- NCT05070689
- Acronym / sponsor ID
- ACCSS / SMDC/SMRC/209-21
- Conditions
- Placenta Accreta
- Keywords
- Peripartum Hystrectomy, Postpartum Haemorrhage
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Sharif Medical Research CenterUniversity, hospital or other
- Study start
- 15 Nov 2021 (actual)
- Primary completion
- 14 Apr 2022 (estimated)
- Study completion
- 31 May 2022 (estimated)
- First posted
- 7 Oct 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Placenta Accreta Spectrum (PAS) disorders are rising in incidence due to increased rate of repeat caesarean sections. Peripartum hysterectomy remains the only definitive treatment of massive postpartum haemorrhage related to this condition. Researchers have described conservative treatments in the form of pelvic devascularization under radiological control, myometrial resection with placenta in situ, and various suturing techniques some involving inversion of cervix. Variable success rates are described, but search continues for a simple, safe and effective treatment. The objective of this study is to assess the simplicity, safety and efficacy of A. Chohan Continuous Squeezing Suture (ACCSS) in the management of PAS.
Detailed description
Placenta accreta spectrum has opened up a new era in the history of PPH, as forcible separation of adherent placenta leads to massive bleeding from placental bed . Peripartum hysterectomy has emerged as gold standard treatment for this variety of PPH (3 folds rise over uterine atony) with its overall morbidity of 40-50%, and mortality of 7-10% in case of placenta percreta . The fear of placental bed bleeding has led to the development of conservative management like "leaving the placenta in situ approach" with its wide range of mild to severe, and serious morbidities . The conservative surgical techniques (The triple P procedure, one step conservative surgery approach) have also used the concept of non-separation of placenta and have instead adopted resection of myometrium with placenta in situ . These surgeries involve devascularisation of deep pelvic / major abdominal vessels and ligation of complex arterial anastomosis making the procedure technically difficult. Moreover, the devascularisation is done under extensive and expensive interventional radiological equipment which places the procedures out of reach for the routine setups particularly in the under developed countries. Another conservative surgical technique (stepwise surgical approach) , which described separation of placenta also mainly relied upon devascularisation of pelvic organs by bilateral ligation of anterior branch of internal iliac artery rather than elaborating the details of technique of controlling haemorrhage at the actual bleeding site.
Rationale of ACCSS ACCSS is a novel suturing technique addresses the management of placenta praevia and PAS following the orthodox approach of separation of placenta, taking the challenge of controlling massive haemorrhage. The rational of ACCSS is; i. Placental bed is the ultimate area of concern in women with placenta praevia and PAS, and it generally spreads over the whole inner surface of lower uterine segment, but the placental attachment and bleeding area upon its separation does not extend onto the internal os and into the vagina.
ii. Lower uterine segment is thin, flexible, squeezable and holds the suture well.
iii. Internal cervical os is a fixed structure, and has a ring with sufficient strength to function as anchor to the suture.
iv. Taking half thickness of internal cervical os into suture does not alter the anatomy and uterine drainage remains unaffected.
- Deep pelvic devascularization by ligation or balloon tamponade occlusion (under radiological control) of deep pelvic vessels was not the part of ACCSS procedure. Bilateral uterine artery ligation was added to it because occlusion of the uterine artery or its branches is useful procedure to stop upper uterine bleeding , it does not appear to affect fertility or obstetric outcome and vascular occlusion is only temporary, as recanalization soon ensures normal uterine circulation . The haemostatic effect of ACCSS is therefore independent and does not rely upon supportive measures.
SURGICAL PROCEDURE The caesarean sections in this study will be performed between 37 and 38 weeks of gestation on all patients. Haematology department will be placed on alert with availability of 4 units of cross matched fresh blood and fresh frozen plasma. All surgeries will be performed by principal investigators (Prof Dr. Arshad Chohan \& Prof. Dr. Fauzia). A multidisciplinary team comprising of experienced obstetricians, anaesthetist, and paediatrician will be involved during the procedure. Prophylactic antibiotic (ceftriaxone 1gm intravenously) will be administered to all patients before surgery.
At caesarean section Pfannenstiel incision will be used for all patients. After opening the abdomen, a clinical assessment about the depth of invasion of the placenta will be made to exclude the involvement of bladder and other pelvic organs. The features noted at this assessment will be abnormal placental bulge and hypervascularity on uterine serosal surface, and placental invasion into the urinary bladder and/or other pelvic organs. Prior to uterine incision placental site will be gently reconfirmed with the examining hand to ascertain an easy fetal access and to avoid cutting of placenta particularly in case of anterior dominant placenta. A transverse incision will be given in the lower uterine segment (LUS) above the insertion of placenta and the baby will be delivered. At delivery of baby10 iu of oxytocin will be given intravenously, followed by 40 iu in 500 ml of normal saline at the rate of 125ml/hour for first 24 hours as per hospital policy for caesarean section for PAS. The uterus will be exteriorized without making any efforts to remove the placenta. The bleeding edges of the uterine incision will be held with Green-Armitage forceps to minimize bleeding. The visceral peritoneum will be displaced downwards with sharp and blunt dissection to allow suturing on the inner side of the LUS. Bladder will be dissected away only if found adherent with the lower uterine segment from previous caesarean sections. Uterine arteries will be ligated on both sides and any blood vessels on the way will be secured. The placenta will then be removed to as close to complete as possible. The lower uterine segment will be packed with sponge to arrest haemorrhage temporarily while preparing for the suture.
ACCSS Application The packing will be removed and the ring of internal os will be identified with the index and middle finger of one hand and held with Babcock forceps with the other hand. On the exposed inner surface of the LUS, suturing will be started from the left corner of uterine incision, using half circle 40mm round body polyglactin 910 suture # 1 (vicryl plus by Ethicon ®) taking multiple half cm bites through half-thickness of the tissue at half cm intervals to reach the outer half of ring of internal os. The suture will then tied and first knot secured causing squeezing of uterine tissue. From here onwards similar sutures will be placed continuously at 1 cm distance till the right corner will be reached, where the second knot will be secured. During suturing the patency of the internal os will be ensured. The continued pull on the suture is expected to cause squeezing of the LUS and arrest bleeding from all sinuses present at the placental site . A similar suture will be applied on the posterior uterine wall in case of bleeding from posterior uterine wall. The suture will be started from the outer half of the posterior lip of the ring of the internal os and going up to the highest bleeding point on the posterior wall of the uterus, continuing from the left to right end of the uterine incision . Any leftover bleeding points will be secured with separate sutures to ensure complete haemostasis. The uterine incision will be closed in two layers as done in a routine lower segment caesarean section. Any additional medical or surgical therapy instituted will be recorded.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Single Group | Experimental | Procedure: ACCSSA. Chohan Continuous squeezing Suture (ACCSS): An obstetrical procedure using half circle 40mm round body polyglactin 910 suture # 1 (Vicryl plus by Ethicon ®) for control of haemorrhage from the lower segment, in patients with Placenta Accreta for the prevention of hysterectomy at caesarean section |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- The women at 32 weeks' gestation with central (anterior dominant, posterior) placenta praevia.
- The women with Placenta Accreta Spectrum disorders having myometrial invasion limited to the uterine serosa (Grade 1, 2, and 3a) without involvement of urinary bladder and other pelvic organs.
- The women wishing to conserve the uterus at the time of caesarean section.
Key exclusion criteria (3 listed)
- The patients with placenta accreta spectrum disorder with bladder and other organs involvement (Grade 3b, 3c) diagnosed prenatally and during caesarean section.
- The patients with laterally situated right and left placentae.
- The recruited patients who required emergency caesarean section.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ACCSSA. Chohan Continuous Squeezing Suture (ACCSS) | Procedure or surgery | Single Group |
Primary outcome
Peripartum Hysterectomy
Time frame: 24 hours
Absolute number of peripartum hysterectomies within the study group
9 secondary outcomes
Application time of suture in minutes
Time frame: within 20 minutes
Estimated blood loss
Time frame: First 24 hours
Number of units of blood transfusions
Time frame: First 24 hours
Intensive care unit admissions
Time frame: 7 days
Duration of stay in hospital
Time frame: 7 days
Urinary tract trauma and its complication
Time frame: 6 weeks
Uterine complications
Time frame: 6 weeks
Secondary postpartum hemorrhage
Time frame: 6 weeks
Maternal mortality
Time frame: 6 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Jan 2022.
- Results publication: PubMed 27843354Ngwenya S. Postpartum hemorrhage: incidence, risk factors, and outcomes in a low-resource setting. Int J Womens Health. 2016 Nov 2;8:647-650. doi: 10.2147/IJWH.S119232. eCollection 2016.
- Results publication: PubMed 31722942Jauniaux E, Gronbeck L, Bunce C, Langhoff-Roos J, Collins SL. Epidemiology of placenta previa accreta: a systematic review and meta-analysis. BMJ Open. 2019 Nov 12;9(11):e031193. doi: 10.1136/bmjopen-2019-031193.
- Results publication: PubMed 31173360Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, Fox KA, Collins S; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2019 Jul;146(1):20-24. doi: 10.1002/ijgo.12761.
- Results publication: PubMed 29843627Huque S, Roberts I, Fawole B, Chaudhri R, Arulkumaran S, Shakur-Still H. Risk factors for peripartum hysterectomy among women with postpartum haemorrhage: analysis of data from the WOMAN trial. BMC Pregnancy Childbirth. 2018 May 29;18(1):186. doi: 10.1186/s12884-018-1829-7.
- Results publication: PubMed 31984808Palacios-Jaraquemada JM, Fiorillo A, Hamer J, Martinez M, Bruno C. Placenta accreta spectrum: a hysterectomy can be prevented in almost 80% of cases using a resective-reconstructive technique. J Matern Fetal Neonatal Med. 2022 Jan;35(2):275-282. doi: 10.1080/14767058.2020.1716715. Epub 2020 Jan 26.
- Individual participant dataSharing planned: No
Related trials for Placenta Accreta
Not yet recruitingObservational study
Placenta-Cervical Interface Angle for Predicting Placenta Accreta Spectrum Severity
Placenta Accreta Spectrum, Placenta Previa
Not yet recruitingObservational study
Hematological and Coagulation Markers in Predicting Placenta Accreta Spectrum in Placenta Previa
Placenta Accreta Spectrum, Placenta Previa
Not yet recruitingObservational study
Ultrasound Scoring System for Diagnosis and Prediction of Severity and Surgical Outcomes of Placenta Accreta Spectrum
Placenta Accreta, Third Trimester
Not yet recruitingObservational study
Total Lower Uterine Segmentectomy With Adjunctive Mechanical Towel Compression for the Surgical Management of Placenta Accreta Spectrum Disorders
Placenta Accreta Management
Recruiting
Comparison Between 3 Conservative Surgeries for Placenta Accreta Spectrum
Placenta Accreta Spectrum
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Muhammad Arshad Chohan, FRCOG principal investigator
Sharif Medical And Dental College
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing ACCSS in people with Placenta Accreta, run by Sharif Medical Research Center at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Jan 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Muhammad Arshad Chohan, FRCOG (+923004027250, marshadchohan@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Peripartum Hysterectomy (time frame: 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05070689, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jan 2022.